Fragment: 176-191 _hot_

Despite the promising pharmacological profile, Fragment 176-191 remains largely in the "research chemical" category.

Fragment 176-191 is a synthetic peptide corresponding to the amino acid sequence 176–191 of the C-terminal region of human Growth Hormone (hGH). It is primarily researched for its lipolytic (fat-burning) and anti-obesity properties. Unlike full-length human Growth Hormone, Fragment 176-191 has been engineered to retain the fat-burning capabilities of hGH while theoretically eliminating the adverse effects associated with the full molecule, such as insulin resistance (diabetogenic effects) and uncontrolled tissue growth (hyperplasia). While promising in preclinical studies, it remains a research chemical with limited human clinical trial data. fragment 176-191

This report is for informational and educational purposes only. Fragment 176-191 is a research chemical and is not approved by the FDA for human consumption or medical treatment. Always consult a medical professional before considering the use of any peptide or hormone therapy. Fragment 176-191 is a research chemical and is

According to Genesis Pub , Fragment 176-191 is noted for its lack of common HGH-related side effects, such as: Human Growth Hormone Fragment 176–191 Peptide ... - PMC Unlike full-length human Growth Hormone